Bailey B Banach, Prabhanshu Tripathi, Lais Da Silva Pereira, Jason Gorman, Thuy Duong Nguyen, Marlon Dillon, Ahmed S Fahad, Patience K Kiyuka, Bharat Madan, Jacy R Wolfe, Brian Bonilla, Barbara Flynn, Joseph R Francica, Nicholas K Hurlburt, Neville K Kisalu, Tracy Liu, Li Ou, Reda Rawi, Arne Schön, Chen-Hsiang Shen, I-Ting Teng, Baoshan Zhang, Marie Pancera, Azza H Idris, Robert A Seder, Peter D Kwong, Brandon J DeKosky
The monoclonal antibody CIS43 targets the Plasmodium falciparum circumsporozoite protein (PfCSP) and prevents malaria infection in humans for up to 9 mo following a single intravenous administration. To enhance the potency and clinical utility of CIS43, we used iterative site-saturation mutagenesis and DNA shuffling to screen precise gene-variant yeast display libraries for improved PfCSP antigen recognition. We identified several mutations that improved recognition, predominately in framework regions, and combined these to produce a panel of antibody variants...
August 1, 2022: Journal of Experimental Medicine